Pediatric Oncology | Specialty

The OncLive Pediatric Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of cancers in pediatric patients, including acute lymphoblastic leukemia, acute myeloid leukemia, brain cancers, sarcomas, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in childhood and adolescent and young adult cancers.

To Advance as a Fellow, Be Open to the Unexpected

May 22nd 2021

YoungNa Lee-Kim, MD, shares advice on how to advance as an oncology fellow.

Dr. Yohe on the Potential to Target RAS Mutations in Pediatric Cancers

May 17th 2021

Marielle E. Yohe, MD, PhD, discusses the potential utility of targeting RAS mutations in pediatric cancers.

NKT Cells Co-Expressing GD2-CAR, IL-15 Can Induce Complete Remissions in Pediatric Neuroblastoma

May 15th 2021

Natural killer T cells that co-express GD2-CAR and interleukin-15 were found to be safe and to demonstrate evidence of in vivo expansion and localization to metastatic sites in patients with stage IV relapsed/refractory neuroblastoma.

Yale Cancer Center Study Shows Cognitive Impairment for Survivors of Many Pediatric Cancers

May 14th 2021

In a new study led by Yale Cancer Center, researchers report many survivors of childhood cancers receive systemic therapies associated with cognitive effects and chronic health conditions that may impact long-term cognitive outcomes with downstream effects on education, employment, and income.

Federico Outlines Needs, Nuances, and Necessities in Neuroblastoma Treatment

May 10th 2021

Sara M. Federico, MD, discusses the diagnosis and presentation of neuroblastoma, the role of multidisciplinary care, and novel therapies that could significantly affect the treatment paradigm for this malignancy.

FDA Grants Priority Review to SH-111 for Pediatric T-Cell Leukemia

April 23rd 2021

The FDA has granted a priority review designation to SH-111, a sterile injectable therapy, for the treatment of pediatric patients with T-cell leukemia.

Resubmission Planned for Omburtamab in Pediatric Metastatic Neuroblastoma

April 20th 2021

As part of a resubmission plan for a biologics license application for omburtamab in pediatric patients with central nervous system and leptomeningeal metastasis from neuroblastoma, Y-mAbs, the manufacturer of the B7-H3–targeting monoclonal antibody, announced that it is collecting additional granularity data requested by the FDA and anticipates submitting them to the regulatory agency by the end of April 2021.

Adavosertib/Irinotecan Shows Early Activity in Pediatric Neuroblastoma

April 12th 2021

Adavosertib plus irinotecan showed early activity in a cohort of pediatric patients with neuroblastoma, thus meeting the protocol-defined efficacy end point of the 1/2 ADVL1312 trial.

Dr. Murphy on the Clinical Implications of Pazopanib Plus SBRT in Pediatric Sarcoma

April 7th 2021

Erin Murphy, MD, discusses the clinical implications of pazopanib plus stereotactic body radiotherapy in pediatric sarcoma.

Dr. Murphy on Future Research Efforts With Pazopanib Plus SBRT in Pediatric Sarcoma

April 6th 2021

Erin Murphy, MD, discusses future research efforts with pazopanib plus stereotactic body radiation therapy in patients with pediatric sarcoma.

Genomic Sequencing Identifies Pediatric Therapy-Related Myeloid Neoplasm Defining Variants Prior to Clinical Presentation

April 5th 2021

Somatic KMT2A rearrangements, RAS/MAPK mutations, RUNX1 and TP53 alterations, and MECOM overexpression were all found to be common oncogenic drivers of pediatric therapy-related myeloid neoplasms, arising predominantly after exposure to cytotoxic therapy and identifiable at least 1 year prior to morphologic evidence of neoplasm.

FDA Approves Daunorubicin/Cytarabine for Pediatric Secondary AML

March 30th 2021

The FDA has approved a revised label for daunorubicin/cytarabine (Vyxeos) to include the treatment of pediatric patients aged 1 year and older with newly diagnosed, therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes.

Dr. Walters on the Drawbacks of Transfusion Dependence in Pediatric Beta-Thalassemia

March 29th 2021

Mark Walters, MD, discusses the limitations of standard blood transfusions in pediatric patients with transfusion-dependent beta-thalassemia.

Pembrolizumab Approved in Europe for Adult and Pediatric Relapsed/Refractory Classical Hodgkin Lymphoma

March 17th 2021

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

Total Body Irradiation Plus Etoposide Improves Survival in Select Transplant-Eligible Pediatric High-Risk ALL

February 25th 2021

Total body irradiation plus etoposide prior to hematopoietic stem cell transplantation resulted in improved overall survival and a lower risk of relapse in pediatric patients with high-risk acute lymphocytic leukemia compared with chemotherapy conditioning.

Dr. Merchant on Incidence of Craniopharyngioma

February 23rd 2021

Thomas E. Merchant, DO, PhD, discusses the incidence of craniopharyngioma.

Dr. Angiolillo on the Toxicity Profile of Traditional Treatment in Pediatric B-ALL

February 22nd 2021

Anne Angiolillo, MD, discusses the adverse effects that are associated with traditional treatment in pediatric B-cell acute lymphoblastic leukemia.

Nichols on Navigating the Nuances of von Hippel-Lindau Disease

February 22nd 2021

In our exclusive interview, Dr. Nichols discusses von Hippel-Lindau disease in great detail, how she currently approaches treatment with these patients, and the importance of routine surveillance in this population.

NCCN Issues First-Ever Guidance for Pediatric Solid Tumor

February 19th 2021

February 19, 2021 - The National Comprehensive Cancer Network has issued guidelines for the management of children with a rare type of kidney cancer referred to as Wilms Tumor, or nephroblastoma.

Reduced Vincristine/Dexamethasone Dosing Schedule Shows Impressive Outcomes, Improved QoL in Pediatric B-ALL

February 19th 2021

A reduced frequency of maintenance vincristine and dexamethasone led to a 5-year overall survival rate of 98.6% and improved quality of life in pediatric patients with newly diagnosed, standard-risk B-cell acute lymphoblastic leukemia.